Literature DB >> 26674651

Cellular Antiviral Factors that Target Particle Infectivity of HIV-1.

Christine Goffinet1.   

Abstract

BACKGROUND: In the past decade, the identification and characterization of antiviral genes with the ability to interfere with virus replication has established cell-intrinsic innate immunity as a third line of antiviral defense in addition to adaptive and classical innate immunity. Understanding how cellular factors have evolved to inhibit HIV-1 reveals particularly vulnerable points of the viral replication cycle. Many, but not all, antiviral proteins share type I interferon-upregulated expression and sensitivity to viral counteraction or evasion measures. Whereas well-established restriction factors interfere with early post-entry steps and release of HIV-1, recent research has revealed a diverse set of proteins that reduce the infectious quality of released particles using individual, to date poorly understood modes of action. These include induction of paucity of mature glycoproteins in nascent virions or self-incorporation into the virus particle, resulting in poor infectiousness of the virion and impaired spread of the infection.
CONCLUSION: A better understanding of these newly discovered antiviral factors may open new avenues towards the design of drugs that repress the spread of viruses whose genomes have already integrated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26674651      PMCID: PMC5403965          DOI: 10.2174/1570162x14666151216145521

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  52 in total

1.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

2.  Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS.

Authors:  S Carl; T C Greenough; M Krumbiegel; M Greenberg; J Skowronski; J L Sullivan; F Kirchhoff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis.

Authors:  Madoka Inuzuka; Minako Hayakawa; Tatsuya Ingi
Journal:  J Biol Chem       Date:  2005-08-24       Impact factor: 5.157

4.  A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men.

Authors:  N C Briggs; C Natoli; N Tinari; M D'Egidio; J J Goedert; S Iacobelli
Journal:  AIDS Res Hum Retroviruses       Date:  1993-09       Impact factor: 2.205

5.  Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer.

Authors:  S Iacobelli; E Arnò; A D'Orazio; G Coletti
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

6.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

7.  IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.

Authors:  Rajini Mudhasani; Julie P Tran; Cary Retterer; Sheli R Radoshitzky; Krishna P Kota; Louis A Altamura; Jeffrey M Smith; Beverly Z Packard; Jens H Kuhn; Julie Costantino; Aura R Garrison; Connie S Schmaljohn; I-Chueh Huang; Michael Farzan; Sina Bavari
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

8.  Semen-derived amyloid fibrils drastically enhance HIV infection.

Authors:  Jan Münch; Elke Rücker; Ludger Ständker; Knut Adermann; Christine Goffinet; Michael Schindler; Steffen Wildum; Raghavan Chinnadurai; Devi Rajan; Anke Specht; Guillermo Giménez-Gallego; Pedro Cuevas Sánchez; Douglas M Fowler; Atanas Koulov; Jeffery W Kelly; Walther Mothes; Jean-Charles Grivel; Leonid Margolis; Oliver T Keppler; Wolf-Georg Forssmann; Frank Kirchhoff
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

9.  The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.

Authors:  M D Miller; M T Warmerdam; I Gaston; W C Greene; M B Feinberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.

Authors:  Yoshiko Usami; Yuanfei Wu; Heinrich G Göttlinger
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

View more
  7 in total

1.  Guanylate binding protein 5: Impairing virion infectivity by targeting retroviral envelope glycoproteins.

Authors:  Dominik Hotter; Daniel Sauter; Frank Kirchhoff
Journal:  Small GTPases       Date:  2016-06-08

Review 2.  SERINC as a Restriction Factor to Inhibit Viral Infectivity and the Interaction with HIV.

Authors:  Gracia Viviana Gonzalez-Enriquez; Martha Escoto-Delgadillo; Eduardo Vazquez-Valls; Blanca Miriam Torres-Mendoza
Journal:  J Immunol Res       Date:  2017-11-22       Impact factor: 4.818

Review 3.  They Might Be Giants: Does Syncytium Formation Sink or Spread HIV Infection?

Authors:  Alex A Compton; Olivier Schwartz
Journal:  PLoS Pathog       Date:  2017-02-02       Impact factor: 6.823

4.  Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1.

Authors:  Greta Forlani; Giovanna Tosi; Filippo Turrini; Guido Poli; Elisa Vicenzi; Roberto S Accolla
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

Review 5.  The Emerging Role of the Serine Incorporator Protein Family in Regulating Viral Infection.

Authors:  Shaofen Xu; Zhichao Zheng; Janak L Pathak; Haoyu Cheng; Ziliang Zhou; Yanping Chen; Qiuyu Wu; Lijing Wang; Mingtao Zeng; Lihong Wu
Journal:  Front Cell Dev Biol       Date:  2022-04-01

Review 6.  Membrane Interference Against HIV-1 by Intrinsic Antiviral Factors: The Case of IFITMs.

Authors:  Federico Marziali; Andrea Cimarelli
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

7.  IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.

Authors:  Yadvinder S Ahi; Diborah Yimer; Guoli Shi; Saliha Majdoul; Kazi Rahman; Alan Rein; Alex A Compton
Journal:  mBio       Date:  2020-01-21       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.